Search for a trial

A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney

• To estimate the difference in the efficacy and safety of RAD001 10 mg p.o. daily dose in combination with bevacizumab 10 mg/kg administered intravenously every two weeks for first-line treatment of patients with metastatic carcinoma of the kidney…

Aspects of bracing in adolescent idiopathic scoliosis

Objective: The primary objective of the study is determining the contributing factors in  bracing for AIS. The contributing factors are determined as factors of influence in the  corrective possibilities and therefore end term…